Candidiasis is a disease myriads encounter across the world and is very difficult to deal with. That issue is caused by a variety of candida species, specifically candida albicans which is common in humans as an opportunistic fungus on our skin and mucous membranes. Our company focuses on addressing the issues of candidiasis and provides solutions to researchers and science professionals through our quality one-stop services.
Overview of Candidiasis
The rate of candidemia is recorded to be around 10 per 100,000 individuals which brings on about 25 thousand cases yearly. The first strong infection of the candida group is candida albicans followed by candida glabrata and candida parapsilosis, then candida tropicalis, and last, candida krusei. Candidiasis can affect different regions of the human body including the skin, mucous, and internal organs, and its degree of presentation may range from mild to very severe, relative to the infected region and its depth.
Fig.1 A schematic diagram showing experimental Candida vaccines. (Sahu, S. R., et al., 2022)
Pathogenesis of Candidiasis
The body's immune system and the tissue-damaging factors of the fungus work together in the emergence of candidiasis. Synthesis of enzymes allows different fungal species of Candida to deeply invade or bind to the host tissues. Morphologically, they can change from one form to another enabling them to adapt to varying host ecosystems. Commingling conditions of the infection, the host's immune reaction, along with the presence of other pathologies, or what drugs are taken, also change the course of the infection and its intensity.
Fig.2 Skin immunity against C. albicans Infection. (Lu, H., et al., 2023)
Vaccine Development for Candidiasis
| Vaccine category |
Name |
Description |
Research Phase |
| Live-attenuated vaccines |
tet-NRG1 |
Filamentation-repressible C. albicans strain tet-NRG1 |
Preclinical research |
| Inactivated vaccines |
HKY |
heat-killed S. cerevisiae yeast (HKY) |
Preclinical research |
| Conjugate |
Lam-CRM197 |
A laminarin conjugated with diphtheria toxoid (CRM197) |
Preclinical research |
| Recombinant |
NDV-3 |
Recombinant N-terminus of Als3p plus alum adjuvant |
Phase I/II trials |
| PEV7 |
A truncated Sap2p embedded into the bilipid layer of an influenza virosomes |
Phase I trials |
| Peptide |
Mimotope-Fba conjugate vaccines |
Fba peptide (14-mer) conjugated with each one of five peptide mimotopes from Met6 (PS2, PS31, PS28, PS55, and PS76) |
Preclinical research |
| DNA vaccines |
Hsp90-CA |
Hsp90-CA-encoding DNA vaccine |
Preclinical research |
Therapeutic Development for Candidiasis
| Name |
Mechanism of Action |
Target |
Research Phase |
| Ibrexafungerp |
A new oral glucan synthase inhibitor |
Glucan synthase |
Phase III trials |
| APX001 |
APX001 is a potent inhibitor of fungal Gwt1, has broad-spectrum antifungal activity against Candida species |
Gwt1 |
Phase II trials |
| Khafrefungin |
An antifungal agent that inhibits inositol phosphorylceramide (IPC) synthase |
IPC synthase |
Preclinical research |
| CMLD013075 |
A highly selective fungal Hsp90 inhibitor |
Hsp90 |
Preclinical research |
| MGCD290 |
Novel Hos2 inhibitor |
Hos2 |
Phase II trials |
Our Services
Our company is ever ready and prepared to assist scientists in all aspects of their research and development projects. The development of disease models, vaccines, therapeutics, and other areas of infectious diseases research is a focal area, and in our company, researchers can find all services and vital information adjoined to each other saving time and resource wastage.
Featured Services of Candidiasis
Infectious Disease Models
- Mouse model of Candida albicans systemic / gastrointestinal / vaginal infection
- Toll-deficient Drosophila melanogaster model
- Caenorhabditis elegans intestinal infection model
- Others
Why Choose Us
Consolidating resources and expertise enables us to provide researchers with the resources needed allowing them to branch out further and help in the innovation of candidiasis research. This will further our knowledge of the important fungal infection.
If you're interested in what we have to offer then feel free to contact us so that we can assist you in your specific research.
References
- Sahu, Satya Ranjan et al. "Vaccines against candidiasis: Status, challenges and emerging opportunity." Frontiers in cellular and infection microbiology 12 (2022): 1002406.
- Lu, Hui et al. "Candidiasis: From cutaneous to systemic, new perspectives of potential targets and therapeutic strategies." Advanced drug delivery reviews 199 (2023): 114960.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
